Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of...
10 insider purchases on record · latest filing 2023-11-21.
Insiders have also filed 80 sale transactions at OMER.